このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Adicet Bio マネジメント

マネジメント基準チェック /24

現在、CEO に関する十分な情報がありません。

主要情報

Chen Schor

最高経営責任者

US$6.0m

報酬総額

CEO給与比率	10.1%
CEO在任期間	4yrs
CEOの所有権	0.2%
経営陣の平均在職期間	3.9yrs
取締役会の平均在任期間	3.3yrs

経営陣の近況

Recent updates

CEO報酬分析

Adicet Bio の収益と比較して、Chen Schor の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Jun 30 2024	n/a	n/a	-US$137m
Mar 31 2024	n/a	n/a	-US$140m
Dec 31 2023	n/a	n/a	-US$143m
Sep 30 2023	n/a	n/a	-US$143m
Jun 30 2023	n/a	n/a	-US$115m
Mar 31 2023	n/a	n/a	-US$105m
Dec 31 2022	US$4m	US$562k	-US$70m
Sep 30 2022	n/a	n/a	-US$56m
Jun 30 2022	n/a	n/a	-US$48m
Mar 31 2022	n/a	n/a	-US$36m
Dec 31 2021	US$10m	US$536k	-US$62m
Sep 30 2021	n/a	n/a	-US$55m
Jun 30 2021	n/a	n/a	-US$56m
Mar 31 2021	n/a	n/a	-US$54m
Dec 31 2020	US$11m	US$499k	-US$37m

報酬と市場: Chenの総報酬 ($USD 5.97M ) は、 UK市場 ($USD 368.02K ) の同規模の企業の平均を上回っています。

報酬と収益: Chenの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Chen Schor (52 yo)

4yrs

在職期間

US$5,973,807

報酬

Mr. Chen Schor, MBA, BA, CPA, serves as Chair of Carbon Biosciences, Inc. He has been the Chief Executive Officer, President & Director at Adicet Bio, Inc since September 15, 2020. He was a Co-Founder of r...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Chen Schor	CEO, President & Director	4yrs	US$5.97m	0.16% $ 180.8k
Aya Jakobovits	Founder & Independent Director	no data	US$240.29k	1.04% $ 1.1m
Brian Harvey	Chief Financial Officer	4yrs	US$2.13m	0.068% $ 75.2k
Donald Healey	Chief Technology Officer	3.9yrs	US$2.09m	0.043% $ 47.2k
Blake Aftab	Senior VP & Chief Scientific Officer	3.4yrs	US$2.48m	0.031% $ 34.1k
Amy Locke	Chief Human Resource Officer	2.7yrs	データなし	データなし
Francesco Galimi	Chief Medical Officer & Senior VP	4yrs	US$1.99m	0.092% $ 101.2k
Nancy Boman	Senior VP & Chief Regulatory Officer	1.8yrs	データなし	データなし

3.9yrs

平均在職期間

59yo

平均年齢

経験豊富な経営陣: 0HX7の経営陣は経験豊富であると考えられます ( 3.8年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Chen Schor	CEO, President & Director	4yrs	US$5.97m	0.16% $ 180.8k
Aya Jakobovits	Founder & Independent Director	4yrs	US$240.29k	1.04% $ 1.1m
Carl Gordon	Independent Chairman	4yrs	US$275.29k	0.0072% $ 7.9k
Steve Dubin	Independent Director	4yrs	US$254.29k	0.013% $ 14.6k
Andrew Sinclair	Independent Director	3.5yrs	US$255.29k	0.0072% $ 7.9k
Jeffrey Chodakewitz	Independent Director	4yrs	US$240.29k	0.0072% $ 7.9k
Marco Davila	Member of Scientific Advisory Board	3.2yrs	データなし	データなし
Lloyd Klickstein	Director	less than a year	US$2.90m	0.12% $ 137.6k
Michael Kalos	Member of Scientific Advisory Board	3.2yrs	データなし	データなし
Saul Priceman	Member of Scientific Advisory Board	3.2yrs	データなし	データなし
Constantine Mitsiades	Member of Scientific Advisory Board	3.2yrs	データなし	データなし
Alice Bertaina	Member of Scientific Advisory Board	3.2yrs	データなし	データなし

3.3yrs

平均在職期間

67yo

平均年齢

経験豊富なボード: 0HX7の取締役会は経験豊富であると考えられます ( 3.5年の平均在任期間)。

Adicet Bio マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Adicet Bio, Inc. Announces Resignation of Michael Kauffman from the Board and Nominating and Corporate Governance Committee

Adicet Bio, Inc. Announces the Appointment of Lloyd Klickstein to its Board of Directors

Adicet Bio, Inc., Annual General Meeting, Jun 05, 2024

Adicet Bio, Inc. Announces Appointment of Katie Peng to the Board of Directors

High number of new and inexperienced directors

High number of new and inexperienced directors

Recent updates

Adicet Bio, Inc Announces ADI-001 Clinical Biomarker Data from the Phase 1 Glean Trial Which Further Reinforces the Potential of ADI-001 as Best-In-Class Allogeneic Cell Therapy for Autoimmune Diseases

Adicet Bio, Inc Announces Strategic Prioritization to Focus ADI-001 Development Resources on Autoimmune Indications

Adicet Bio, Inc. Announces Resignation of Michael Kauffman from the Board and Nominating and Corporate Governance Committee

Adicet Bio, Inc. Announces the Appointment of Lloyd Klickstein to its Board of Directors

Adicet Bio, Inc.(NasdaqGM:ACET) dropped from Russell 2500 Value Index

Adicet Bio Receives FDA Fast Track Designation for ADI-001 in Lupus Nephritis

Adicet Bio, Inc., Annual General Meeting, Jun 05, 2024

Adicet Bio, Inc. Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the ASGCT 27th Annual Meeting

Adicet Bio, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

New major risk - Shareholder dilution

New minor risk - Shareholder dilution

Adicet Bio, Inc. has completed a Follow-on Equity Offering in the amount of $85.199155 million.

Adicet Bio, Inc. Highlights ADI-001 Expansion, Persistence and Pharmacodynamic Profile from Ongoing Phase 1 Study At the 65Th American Society of Hematology Annual Meeting

New minor risk - Market cap size

Adicet Bio, Inc. Announces Appointment of Katie Peng to the Board of Directors

New minor risk - Market cap size

Adicet Bio Reports Positive Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL)

Adicet Bio, Inc. Presents Positive Preclinical Data on ADI-270 At the American Society of Gene and Cell Therapy (ASGCT) 26Th Annual Meeting

Full year 2022 earnings released: US$1.70 loss per share (vs US$2.00 loss in FY 2021)

High number of new and inexperienced directors

High number of new and inexperienced directors

Adicet Bio, Inc. Reports Positive Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL)

Adicet Bio Inc. Appoints Nancy Boman, as Senior Vice President and Chief Regulatory Officer

High number of new and inexperienced directors

Adicet Bio, Inc. Reports ASH Abstract Data from Ongoing ADI-001 Phase 1 Trial in Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

High number of new and inexperienced directors

Second quarter 2022 earnings released: US$0.56 loss per share (vs US$0.34 loss in 2Q 2021)

Adicet Bio, Inc. Reports Emerging Data from ADI-001 Phase 1 Trial at the American Society of Clinical Oncology Annual Meeting

Adicet Bio, Inc. Reports Positive Clinical Update from ADI-001 Phase 1 Trial in Relapsed/Refractory Non-Hodgkin’s Lymphoma (NHL)

First quarter 2022 earnings released: EPS: US$0.12 (vs US$0.82 loss in 1Q 2021)

Adicet Bio, Inc. Presents Preclinical Data at ISCT Annual Meeting Highlighting Potential Advantages of Non-Gene-Edited Approach for its Investigational Allogeneic Gamma Delta Car T Cell Therapy Targeting CD20 for B Cell Malignancies

High number of new and inexperienced directors

Adicet Bio, Inc. Announces Oral Presentation of Updated ADI-001 Phase 1 Data at the 2022 American Society of Clinical Oncology Annual Meeting

Adicet Bio, Inc., Annual General Meeting, Jun 02, 2022

Adicet Bio Receives FDA Fast Track Designation for Lead Candidate ADI-001

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

High number of new and inexperienced directors

Adicet Bio Announces Positive Interim Clinical Data from First-Ever Allogeneic, Off-The-Shelf, Gamma Delta Car T Investigational Cell Therapy

Third quarter 2021 earnings released: US$0.44 loss per share (vs US$2.84 loss in 3Q 2020)

High number of new and inexperienced directors

Second quarter 2021 earnings released: US$0.34 loss per share (vs US$0.48 loss in 2Q 2020)

Adicet Bio, Inc.(NasdaqGM:ACET) dropped from Russell 3000E Growth Index

Senior VP, Chief Scientific & Operating Officer Stewart Abbot has left the company

Adicet Bio, Inc., Annual General Meeting, Apr 27, 2021

Revenue beats expectations

Full year 2020 earnings released: US$5.01 loss per share (vs US$1.63 loss in FY 2019)

Adicet Bio, Inc. Announces Initiation of its First-In-Human Phase 1 Trial of ADI-001 for the Treatment of B Cell Non-Hodgkin's Lymphoma

Adicet Bio, Inc. Announces Board Changes

Director has left the company

Adicet Bio, Inc. Announces Resignation of Lloyd Klickstein as Chief Innovation Officer

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /24